ProKidney Corp. reported continued advancement of its Phase 3 PROACT 1 trial for rilparencel, a cell therapy targeting kidney diseases, with topline pivotal data expected in Q2 2027. The company has secured FDA agreement to pursue accelerated approval leveraging eGFR slope as a surrogate endpoint, underscoring a streamlined regulatory path. Despite posting a net loss for Q1 2026, ProKidney maintains a robust cash position exceeding $100 million and a current ratio above 9, providing operational runway into mid-2027. The company’s proprietary cell therapy platform is strategically focused on an underserved renal disease market with significant unmet needs.